Regeneron Pharmaceuticals (REGN) Shares Outstanding (Weighted Average) (2009 - 2026)

Regeneron Pharmaceuticals' Shares Outstanding (Weighted Average) history runs 18 years deep, the most recent figure standing at $104.0 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) fell 2.53% year-over-year to $104.0 million; the TTM figure through Mar 2026 stood at $104.0 million (down 2.53% YoY), while the FY2025 annual figure was $104.6 million, down 3.06% from the prior year.
• Shares Outstanding (Weighted Average) was $104.0 million for Q1 2026 at Regeneron Pharmaceuticals, down from $104.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $108.1 million in Q3 2024 to a low of $103.6 million in Q3 2025.
• Historically, Shares Outstanding (Weighted Average) has averaged $106.6 million across 5 years, with a median of $107.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Weighted Average) gained 2.0% in 2022, then fell 4.16% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $107.1 million in 2022, then dropped by 0.37% to $106.7 million in 2023, then rose by 1.12% to $107.9 million in 2024, then declined by 3.06% to $104.6 million in 2025, then retreated by 0.57% to $104.0 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $104.0 million (Q1 2026), $104.6 million (Q4 2025), and $103.6 million (Q3 2025), per Business Quant data.